Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T12:50:17.642Z.
Calculation as of: 2026-10-06T12:50:17.642Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 79e645a94fbd5e366445fb8f0b2dfca38265e5d6ea8975ca37c6e7b4421e0c07
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Aardvark Therapeutics, Inc. Common Stock
Market Cap
$114.24M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$111.17M
Price/FCF Ratio
N/A
TTM Avg
8.08
3Y Avg
8.08
5Y Avg
8.08
Market Cap
$117.43M
Price/FCF Ratio
N/A
TTM Avg
1.66
3Y Avg
1.66
5Y Avg
1.66
Market Cap
$118.02M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$118.50M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $114.24M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | N/A | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $116.59M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | N/A | 8.08 | 8.08 | 8.08 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $117.43M | N/A | 1.66 | 1.66 | 1.66 |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | N/A | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $118.50M | N/A | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $109.93M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $118.63M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.49M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
